B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $175
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad has maintained a Buy rating on Ascendis Pharma and increased the price target from $165 to $175.
September 04, 2024 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has reaffirmed its Buy rating on Ascendis Pharma and increased the price target to $175, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and an increased price target from a reputable analyst suggests a positive outlook for Ascendis Pharma, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100